Table 5.
Summary of clinical trials using compounds to modulate the expression of different CAMs.
| Drug | Target | Disease | Mechanism | ClinicalTrials.gov Identifier | Reference |
|---|---|---|---|---|---|
| Natalizumab | VLA-4 | Multiple myeloma | Monoclonal antibody | NCT00675428 | |
| Natalizumab | VLA-4 | B-ALL | Monoclonal antibody | Pre-clinical | (20) |
| AS101 | VLA-4 | Adult AML | Redox inactivation | NCT01010373 | (22) |
| FNIII14 | VLA-4 | AML | Antagonism | Pre-clinical | (101) |
| TBC3486 | VLA-4 | B-ALL | Ligand-mimetic | Pre-clinical | (21) |
| LFA703 | LFA-1 | Multiple myeloma | Antagonism | Pre-clinical | (25) |
| GMI-1271 | E-selectin | AML | Antagonism | NCT02306291 | (32) |
| GMI-1359 | CXCR4, E- selectin | AML | Antagonism | Pre-clinical | (47) |
| Hu5F9-G4 | CD47 | AML | Antagonism | NCT02216409 | (38) |
| BI-505 | ICAM-1 | Multiple myeloma | Monoclonal antibody | NCT01025206 | (49) |
| Plerixafor | CXCR4 | AML | Antagonism | NCT00906945 | (43) |
| Plerixafor | CXCR4 | Acute leukemia | Antagonism | NCT01068301 | (44) |
| MDX-1338 | CXCR4 | AML | Monoclonal antibody | NCT01120457 | (46) |
| POL5551 | CXCR4 | High-risk ALL | Antagonism | Pre-clinical | (45) |
| Lenalidomide | ICAM-1, VCAM-1 | Multiple myeloma | Downregulation of TNFα | NCT00772915 | (105) |
| Lenalidomide | ICAM-1, VCAM-1 | Acute AML | Downregulation of TNFα | NCT01615042 | (52) |